Page 12 - Ndpoint Threat Detection And Response News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ndpoint threat detection and response. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ndpoint Threat Detection And Response Today - Breaking & Trending Today

Takeda Announces Results From Phase 4 Vedolizumab Study in Patients With Chronic Pouchitis Published in New England Journal of Medicine

−The Phase 4 EARNEST Study Met Its Primary Efficacy Endpoint of Remission of Chronic or Recurrent Pouchitis at Week 14, with 31% of Participants Receiving Vedolizumab Achieving Remission versus. | March 30, 2023 ....

United States , Simon Travis , John Cunningham , Fachinformation Entyvio , Marcelo Freire , Exchange Commission , Global Medical Affairs , European Union , Kennedy Institute , University Of Oxford , Takeda Pharmaceutical Company Limited , New England Journal , Professor Simon Travis , Translational Gastroenterology Unit , Vice President , Therapeutic Area Head , Safety Information , Special Precautions , Site Reactions , Product Characteristics , Prescribing Information , Medication Guide , Rare Genetics , Plasma Derived Therapies , Annual Report , Inflamm Bowel ,

VistaGen Therapeutics : Press Release issued by Vistagen Therapeutics, Inc., dated March 30, 2023 - Form 8-K

FDA Provides Positive Feedback to Vistagen Regarding Use of the Liebowitz Social Anxiety Scale as an Endpoint in Phase 3 Development of Fasedienol for Treatment of Social Anxiety. | March 30, 2023 ....

New York , United States , Columbia University , New York State Psychiatric Institute , Shawn Singh , Mark Mcpartland , Nate Hitchings , Michaelr Liebowitz , Company Phase , Drug Administration , York State Psychiatric Institute , Development Of Fasedienol , Additional Fasedienol Program Updates , Research Network , Exchange Commission , Positive Feedback , Vistagen Regarding Use , Liebowitz Social Anxiety Scale , Social Anxiety , New Drug Application , Anxiety Disorders Clinic , Managing Director , Medical Research Network , New York City , Principal Investigator , Chief Executive Officer ,

Intra-Cellular Therapies Announces Positive Topline Results from Study 403 Evaluating Lumateperone as Monotherapy in Patients with Major Depressive Disorder with Mixed Features and Bipolar Depression with Mixed Features

Lumateperone 42mg was statistically significant on the primary endpoint of symptom reduction on the Montgomery Asberg Depression Rating Scale for each patient population including: -combined major. | March 28, 2023 ....

Juan Sanchez , Cameron Radinovic , Burns Mcclellan Inc , Globenewswire Inc , Corporate Communications , Exchange Commission , Cellular Therapies Inc , Montgomery Asberg Depression Rating Scale , Global Impression , Severity Scale , Cellular Therapies , About Study , Statistical Manual , Mental Disorder , Young Mania Rating , About Mixed Features , Bipolar Depression , Major Depressive , Adverse Reactions , Elderly Patients , Dementia Related Psychosis , Boxed Warning , Malignant Syndrome , Blood Pressure , Private Securities Litigation Reform Act , Intra Cellular Therapies ,

Novartis Gets Positive Result From Breast-Cancer Drug Trial

By Cecilia Butini

Novartis AG said Monday that a trial evaluating breast-cancer drug Kisqali met its primary endpoint during an interim analysis.

The drug is shown to significantly reduce. | March 27, 2023 ....

Cecilia Butini , Dow Jones , Novartis Ag Stock Exchange , Press Release , Ignificantly Novn Ch0012005267 ,

Live Webinar | 5 Ways Identity Strengthens Cyber Security for the Enterprise

. bank information security ....

Access Management , Identity Strengthens Cyber Security , Hybrid Environments , Cloud Adoption , Digital Identities , Cyber Attacks , Isky Users ,